Analysis of Clinical Prognostic Factors for Adult Patients with Head and Neck Sarcomas

ObjectiveTo evaluate the treatment, outcome, and prognostic factors in patients with head and neck sarcomas treated in an academic medical center. Study DesignCase series. SettingAcademic medical center. Subjects and MethodsWe performed a retrospective analysis of adult patients (n = 97) with primary head and neck sarcomas treated between 2000 and 2012. We analyzed the treatment, outcome, and potential factors predictive of disease-free survival and disease-specific survival. We also evaluated the outcome and prognostic factors in patients with bone and soft tissue sarcomas. ResultsThe median overall survival was 6.8 years, with 2-year and 5-year overall survival rates of 78% (95% confidence interval [CI], 66%-86%) and 59% (95% CI, 44%-72%), respectively. Univariable analysis revealed that age at diagnosis (>60 years: hazard ratio [HR], 2.7; 95% CI, 1.2-6.2; P =. 01), surgical intervention (HR, 8.3; 95% CI, 3.5-19.5; P <. 001), and metastatic disease (HR, 4.3; 95% CI, 1.3-13.6; P =. 01) were significantly associated with disease-specific survival. ConclusionIn this study, patients over the age of 60 years at diagnosis and those with inoperable disease at initial presentation had significantly worse disease-specific survival. Surgical intervention remains the optimal treatment modality for those with resectable disease and was associated with significantly better survival in this heterogeneous series. Further multi-institutional studies are required to better define prognostic factors in individual histological subtypes.